Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms

Considerable clinical experience regarding the long-term efficacy and safety of ruxolitinib has been gathered since the drug was approved in the USA for patients with intermediate or high-risk myelofibrosis (MF) in November 2011. Findings from the pivotal phase 3 COMFORT studies showed that ruxoliti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yacoub, A., Odenike, O., Verstovsek, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Myeloproliferative Disorders (C Harrison, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223534/
https://www.ncbi.nlm.nih.gov/pubmed/25145552
http://dx.doi.org/10.1007/s11899-014-0229-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223534/
https://www.ncbi.nlm.nih.gov/pubmed/25145552
http://dx.doi.org/10.1007/s11899-014-0229-y

Ejemplares similares